Abstract:The clinical skeletal imaging performed by injection of 99Tcm-MDP,has to wait for 2～3 h so as to reduce the background radiation,the low radiochemical purity of 99Tcm-MDP may be the major cause so that its radiochemical purity was assessed by so-called one-strip in 2002,i.e.ascending thin-layer chromatography with one silica gel strip as the stationary phase and V(10% ammonium)∶V(acetate-methanol)=1∶1 as the mobile phase.After developing and drying this strip was tested by autoradiography.In 2008 99Tcm-MDP and the other five 99Tcm radiopharmaceuticals as 99TcmO4-,99Tcm-EC,99Tcm-DTPA,99Tcm-MIBI and 99Tcm-MAA were assessed by these methods as mentioned above,but the only difference was the self-developing film instead of traditional X ray film.The autoradiogram of 99Tcm-MDP was observed by naked eye and the results showed that the radiochemical purity of 99Tcm-MDP was higher than that in 2002,and the Rf values of 0.7 was assessed.Using these methods assessed 99Tcm-DTPA,99Tcm-MIBI and 99Tcm-MDP in 2009 respectively,the autoradiogram of former two drugs was as same as that in 2008,and the Rf average value was 0.78±0.02 and 0.39±0.03 separately.The Rf values of two 99Tcm-MDP samples were all closed to zero,which were rather different from those in 2008.It might be that 99Tcm-MDP was a composite compound of characteristics of 99Tcm-Sn colloid,in the storing effective time for 52 weeks,since the decrease of contents of stannous chloride in the box caused the significant change of Rf value,which could not be measured by two-strip method(one strip for free pertechtate,one strip for 99Tcm-Sn colloid).It is suggested that the drug manufacturers should continue to study to find out the optimum TLC for testing the radiochemical purity of 99Tcm radiopharmaceuticals,after the components are separated completely,calculate the radiochemical purity or 99Tcm labeling efficiency by using these peak areas of the radioactive curve.The normalization of 99Tcm radiopharmaceuticals measuring method might be helpful for the further developing radiopharmacy.

Preparation and Evaluation of 188re(ⅴ) -DMSA Kit

Preparation and evaluation of 188Re(V) -DMSA kit

Preparation of (188re) Re-AEDP and Its Biodistribution Studies.

The Preparation of 188Re-Aedp

Synthesis and Analysis of Two Versions of Radioisotope Carbon-14 Labelled Dufulin

Synthesis and analysis of carbon-14 labelled Dufulin with high specific activity

Biodistribution of 188Re-Aedp in Rats and Its Dependenceon Rhenium Carrier

Preparation of 188W/188Re Generator With a Clinical-meaning

Tissue Distribution Study of Dimercaptosuccinic Acid in Mice by HPLC-Fluorescence Method

Preparation of 188Re-Mag3 and in Vivo Evaluation in Mice

Preparation and Preliminary Biological Evaluation of 99Mtc-Anmdu

Preparation of (188)~w/(188)~re Generator in a Clinical-Scale

Synthesis, Characterization and Evaluation of BSA - (Gd - DTPA)_n as a MRI Contrast Agent Precursor

Experimental Study On"one-Strip"thin-layer Chromatography for Determining the Radiochemical Purity of 99tcm Radiopharmaceuticals

Preparation and Preliminary Biological Evaluation of 11C-L-spd

Review of a New Molecular Imaging Method——Deuterium Metabolic Spectroscopy and Imaging

The Labeling of EDTMP with ~(188)re and Its Distribution in Mice

The Development of Dendritic Gd-Dtpa Complexes for Mri Contrast Agents

^188 Re Labeled MPEG-modified Superparamagnetic Nanogels：preparation and Preliminary Application in Mice

Preparation of ~(177)Lu-DOTA/DTPA-Bz-Cys-RGD Dimer and Biodistribution Evaluation in Normal Mice

Preparation Of~(188)re-Lanreotide As a Potential Tumor Therapeutic Agent